272773-11-2 Usage
General Description
3-Bromo-5-isoxazolecarboxylic acidmethylester is a chemical compound that is a derivative of isoxazolecarboxylic acid. It is a colorless liquid with a molecular formula of C6H5BrNO3 and a molecular weight of 214.012 g/mol. 3-Bromo-5-isoxazolecarboxylic acidmethylester is commonly used as a building block for the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds. It is also used as an intermediate in the synthesis of herbicides and plant growth regulators. 3-Bromo-5-isoxazolecarboxylic acidmethylester is known for its potential applications in the fields of medicine, agriculture, and chemical research.
Check Digit Verification of cas no
The CAS Registry Mumber 272773-11-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,7,2,7,7 and 3 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 272773-11:
(8*2)+(7*7)+(6*2)+(5*7)+(4*7)+(3*3)+(2*1)+(1*1)=152
152 % 10 = 2
So 272773-11-2 is a valid CAS Registry Number.
InChI:InChI=1/C5H4BrNO3/c1-9-5(8)3-2-4(6)7-10-3/h2H,1H3
272773-11-2Relevant articles and documents
Design, synthesis and biological study of potent and covalent HER-2 tyrosine kinase inhibitors with low cytotoxicity in vitro
Jin, Shuyu,Sun, Xiuyun,Liu, Dan,Xie, Hua,Rao, Yu
, p. 1333 - 1345 (2019)
The discovery and development of a novel HER-2 tyrosine kinase inhibitor for the treatment of HER2-positive breast cancer are presented in this article. EGFR family has been recognized as a crucial meditator in the cancer progression; HER-2 tyrosine kinase was one of the members among them. In the effort to explore potent HER-2 inhibitors, a novel series of 4-anilino-3-cyanoquinoline derivatives have been designed, synthesized and evaluated. Most compounds possessed modest proliferation inhibition on SK-BR-3 cell line and HER-2 kinase. Compound 16 appeared to be the most potent compound (HER-2 kinase IC50: 19.4?nM, SK-BR-3 IC50: 94?nM). In the experiment of cellular cytotoxicity assay, compound 16 shows a much lower cytotoxicity than neratinib on Beas-2b cell line (Human bronchial epithelial cells). In conclusion, compound 16 would be a promising lead compound for further anti-breast cancer drug discovery.
